Multimodal Study of the Human Brain Epilepsy Tissue (TIPI²)
Primary Purpose
Focal Drug-resistant Epilepsy
Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Blood and tissue collection
Sponsored by
About this trial
This is an interventional basic science trial for Focal Drug-resistant Epilepsy focused on measuring Focal drug-resistant epilepsy, Surgery, Biorepository, Biomarkers
Eligibility Criteria
Inclusion Criteria: 18 yo or above patients with a focal drug-resistant epilepsy patients hospitalized for a pre-surgical evaluation or for an epilepsy surgery consent obtained from the patient, or legally authorized representative affiliated to a social security system Exclusion Criteria: None
Sites / Locations
- Department of Neurology, Epilepsy Unit, Pitié-Salpêtrière Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
epileptic patients
Arm Description
All patients will be enrolled in the same arm. Patients can be enrolled during the pre-surgical evaluation (group 1) or in the days preceding the surgery (group 2).
Outcomes
Primary Outcome Measures
Identification of new pathophysiological mechanisms leading to focal drug-resistant epilepsy : analysis by immuno-histological methods
The investigator will identify inflammatory cells (astrocytes, microglia, lymphocytes and neutrophil polynuclear cells) in the post-operative brain tissue, and will calculate if there is an increase of a part of these cells in the area, defined as the seizure onset zone, as compared to the non-epileptic areas.
Identification of new pathophysiological mechanisms leading to focal drug-resistant epilepsy : analysis by electrophysiological methods
The investigator will record local field potentials and neuronal firing rate from post-operative tissues, and we will research an increase of the rate of interictal epileptiform discharges and of the frequency of the neuronal firing in the seizure-onset zone, as compared to those in non-epileptic areas.
Identification of new pathophysiological mechanisms leading to focal drug-resistant epilepsy : analysis by RNA sequencing methods
The investigator will measure the expression of mRNA in cells of different parts of the post-operative brain tissue, and we will research specific expression of mRNA in the Seizure onset zone, as compared to that in other non-epileptic areas.
Secondary Outcome Measures
Identification of new pathophysiological mechanisms associated with the occurrence of a seizure : analysis of biomarkers by ELISA methods
The investigator will measure several proteins by Elisa, and we will define if there is a specific increase of some proteins in the sample after a seizure, as compared to the level of these proteins far from a seizure.
Identification of new pathophysiological mechanisms associated with an active epilepsy : analysis of biomarkers by ELISA methods
The investigator will measure the different blood cells by flow cytometry, and we will define if there is a specific increase of some cell populations in the sample from epileptic patients, as compared to the level of these cell populations in non-epileptic patients.
Identification of new pathophysiological mechanisms associated with an active epilepsy : analysis of blood cell subtypes by flow cytometry
The investigator will measure the different blood cells by flow cytometry, and we will define if there is a specific increase of some cell populations in the sample from epileptic patients, as compared to the level of these cell populations in non-epileptic patients.
Identification of new pathophysiological mechanisms associated with an active epilepsy : analysis of inflammation biomarkers by digital ultra-sensitive quantitation of proteins methods
The investigator will measure several inflammatory proteins including cytokines, and we will define if there is a specific increase of some proteins in the sample from epileptic patients, as compared to the level of these proteins in non-epileptic patients.
Full Information
NCT ID
NCT06022055
First Posted
May 22, 2023
Last Updated
August 30, 2023
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
ICM Co. Ltd., Institut National de la Santé Et de la Recherche Médicale, France
1. Study Identification
Unique Protocol Identification Number
NCT06022055
Brief Title
Multimodal Study of the Human Brain Epilepsy Tissue
Acronym
TIPI²
Official Title
Multimodal Study of the Human Brain Epilepsy Tissue
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 1, 2023 (Anticipated)
Primary Completion Date
October 1, 2029 (Anticipated)
Study Completion Date
October 1, 2036 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
ICM Co. Ltd., Institut National de la Santé Et de la Recherche Médicale, France
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The TIPI2 study is a blood and tissue collection protocol to create an annotated biorepository to support research in drug-resistant epilepsy.
The aim of the study will be to identify new pathophysiological pathways. For this purpose, the investigators will investigate with a multimodal approach blood and brain samples from patients undergoing a surgery for focal drug-resistant epilepsy. The adult patients will be enrolled either during the pre-surgical evaluation or right before the surgery.
Detailed Description
This study aims to investigate blood and brain samples from patients with drug-resistant epilepsy in order to identify new pathophysiological biomarkers.
The investigators will first conduct multimodal research, including:
electrophysiological analyses
immunohistochemistry and genetic studies
biochemistry analyses
Samples will be stored at -80°C for future research.
Patients will undergo a follow-up evaluation within the 36 months following the surgery. New clinical data and biological samples will be collected then.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Focal Drug-resistant Epilepsy
Keywords
Focal drug-resistant epilepsy, Surgery, Biorepository, Biomarkers
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
epileptic patients
Arm Type
Experimental
Arm Description
All patients will be enrolled in the same arm. Patients can be enrolled during the pre-surgical evaluation (group 1) or in the days preceding the surgery (group 2).
Intervention Type
Other
Intervention Name(s)
Blood and tissue collection
Intervention Description
Blood will be collected for group 1 during (i) the enrolment visit, (ii) in the 24 hours following a seizure, (iii)before the surgery and (iv) in the 36 months following the surgery. The left-over tissue, not useful for diagnostic purpose, will be kept for research.
Blood will be collected for group 2 right before the surgery and in the 36 months following the surgery. The left-over tissue not useful for diagnostic purpose will be kept for research.
Primary Outcome Measure Information:
Title
Identification of new pathophysiological mechanisms leading to focal drug-resistant epilepsy : analysis by immuno-histological methods
Description
The investigator will identify inflammatory cells (astrocytes, microglia, lymphocytes and neutrophil polynuclear cells) in the post-operative brain tissue, and will calculate if there is an increase of a part of these cells in the area, defined as the seizure onset zone, as compared to the non-epileptic areas.
Time Frame
At the day of surgery; analyses are based on the post-operative tissues
Title
Identification of new pathophysiological mechanisms leading to focal drug-resistant epilepsy : analysis by electrophysiological methods
Description
The investigator will record local field potentials and neuronal firing rate from post-operative tissues, and we will research an increase of the rate of interictal epileptiform discharges and of the frequency of the neuronal firing in the seizure-onset zone, as compared to those in non-epileptic areas.
Time Frame
At the day of surgery; analyses are based on the post-operative tissues
Title
Identification of new pathophysiological mechanisms leading to focal drug-resistant epilepsy : analysis by RNA sequencing methods
Description
The investigator will measure the expression of mRNA in cells of different parts of the post-operative brain tissue, and we will research specific expression of mRNA in the Seizure onset zone, as compared to that in other non-epileptic areas.
Time Frame
At the day of surgery; analyses are based on the post-operative tissues
Secondary Outcome Measure Information:
Title
Identification of new pathophysiological mechanisms associated with the occurrence of a seizure : analysis of biomarkers by ELISA methods
Description
The investigator will measure several proteins by Elisa, and we will define if there is a specific increase of some proteins in the sample after a seizure, as compared to the level of these proteins far from a seizure.
Time Frame
from inclusion day to 36 months after the surgery
Title
Identification of new pathophysiological mechanisms associated with an active epilepsy : analysis of biomarkers by ELISA methods
Description
The investigator will measure the different blood cells by flow cytometry, and we will define if there is a specific increase of some cell populations in the sample from epileptic patients, as compared to the level of these cell populations in non-epileptic patients.
Time Frame
from inclusion day to 36 months after the surgery
Title
Identification of new pathophysiological mechanisms associated with an active epilepsy : analysis of blood cell subtypes by flow cytometry
Description
The investigator will measure the different blood cells by flow cytometry, and we will define if there is a specific increase of some cell populations in the sample from epileptic patients, as compared to the level of these cell populations in non-epileptic patients.
Time Frame
from inclusion day to 36 months after the surgery
Title
Identification of new pathophysiological mechanisms associated with an active epilepsy : analysis of inflammation biomarkers by digital ultra-sensitive quantitation of proteins methods
Description
The investigator will measure several inflammatory proteins including cytokines, and we will define if there is a specific increase of some proteins in the sample from epileptic patients, as compared to the level of these proteins in non-epileptic patients.
Time Frame
from inclusion day to 36 months after the surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 yo or above
patients with a focal drug-resistant epilepsy
patients hospitalized for a pre-surgical evaluation or for an epilepsy surgery
consent obtained from the patient, or legally authorized representative
affiliated to a social security system
Exclusion Criteria:
None
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vincent M. Navarro, MD, PHD
Phone
01 42 16 19 40
Ext
+33
Email
Vincent.navarro@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Aurélie Ms Hanin, PharmD, PhD
Phone
01 57 27 40 56
Ext
+33
Email
Aurelie.hanin@icm-institute.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vincent M. Navarro, MD, PHD
Organizational Affiliation
APHP
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Neurology, Epilepsy Unit, Pitié-Salpêtrière Hospital
City
Paris
ZIP/Postal Code
75013
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vincent M. Navarro, MD, PHD
Phone
01 42 16 19 40
Ext
+33
Email
Vincent.navarro@aphp.fr
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Data are available upon reasonable request
The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients.
Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
IPD Sharing Time Frame
Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor.
IPD Sharing Access Criteria
Researchers who provide a methodologically sound proposal.
Learn more about this trial
Multimodal Study of the Human Brain Epilepsy Tissue
We'll reach out to this number within 24 hrs